A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers
Status:
Completed
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, parallel-group, phase 1 study to evaluate the PD effect of
AP301 capsule in healthy volunteers. The study is planned to have 4 treatment arms: Arm 1:
2.10 g/day; arm 2: 4.20 g/day; arm 3: 6.30 g/day; arm 4: 8.40 g/day.